Fred M. Schwarzer

Mr. Schwarzer has served as our Chief Executive Officer since July 2010 and has been a member of our board of directors since February 2003, serving as Chairman until August 2018. Mr. Schwarzer has also served as our President since December 2018, and previously served as Chief Executive Officer and President at different times between December 1999 and May 2003. Mr. Schwarzer was a founder of Charter Life Sciences, a venture capital firm specializing in life sciences investments, in 2003 and served as its Managing Partner from inception until August 2019. Mr. Schwarzer previously served as Chair of the board of directors of Inviragen, a biopharmaceutical company and developer of the DENVax dengue vaccine, from 2009 until Inviragen’s acquisition by Takeda Pharmaceutical Company in 2013. He also served as Chief Executive Officer and Chairman of the board of directors of Heska Corporation, a biotechnology company focused primarily on the animal healthcare markets, from 1994 to 1998 and 1999 to 2001, respectively. Mr. Schwarzer received a B.A in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.

Bruce Keyt, Ph.D. 

Dr. Keyt has served as our Chief Scientific Officer since August 2012 and previously served as a consultant beginning in August 2010. Prior to joining us, Dr. Keyt served as Chief Technology Officer at Trellis Bioscience, an antibody discovery company, from August 2007 to February 2010. Earlier in his career, he served as Head of Research between 2005 and 2006 at Abmaxis, a biotechnology company, which was acquired by Merck. He was the Vice President of Preclinical Development at Abgenix, a biotechnology company, from 2001 through the acquisition of Abgenix by Amgen in 2005. Dr. Keyt was the Director of Pharmacology at Millennium Pharmaceuticals from 1998 to 2001. From 1982 to 1998, he served in research and development roles at Roche/Genentech as a Scientist and Senior Scientist, where he made significant contributions to the discovery and development of Avastin, Lucentis, Activase tPA, TNKase-tPA and Kogenate. Dr. Keyt received a B.A. in Chemistry from Washington University in St. Louis and a Ph.D. in Biochemistry from Tufts University School of Medicine.

Carrie Brodmerkel, Ph.D.

Dr. Brodmerkel has served as Chief Scientific Officer, IGM Autoimmunity and Inflammation since 2022. She brings extensive experience across a broad range of disciplines.  While the majority of Dr. Brodmerkel’s experience is in autoimmunity and inflammation, she also has experience in solid tumor oncology and hematology. Most recently, Dr. Brodmerkel served as the Vice President and Global Head of Exploratory Biology and Scientific Strategy at Janssen R&D, a division of Johnson & Johnson, where she was responsible for scientific and strategic leadership of the biotherapeutics portfolio, functional planning and execution, computational sciences, and exploratory biology across therapeutic areas including immunology, hematology, and oncology.  During her 16 years at  Janssen, Carrie served in multiple roles of increasing responsibility including cross-functional matrix leader roles, and heading biomarker and systems pharmacology for immunology.  Prior to Janssen, Carrie was with Incyte and Dupont Pharmaceuticals, where she was focused on discovery biology in the area of  chemokines and inflammation.  Dr. Brodmerkel obtained her B.S. in Neuroscience from the University of Pittsburgh and her Ph.D. in Pathology at the Albert Einstein College of Medicine, where her dissertation focused on the role of chemokines in inflammation of the central nervous system.

Albert Candia, Ph.D.

Dr. Candia joined us in 2022 as Senior Vice President of Preclinical Sciences. Dr. Candia brings over 22 years of biotechnology experience to IGM in both research and development in a variety of therapeutic areas and drug modalities. Prior to joining IGM, he was Vice President of Bioanalytical Development at Nektar Therapeutics, leading cross functional teams supporting clinical development and chemistry, manufacturing and control. Dr. Candia has also held previous positions at Dynavax Technologies and Xencor, where he oversaw IND enabling, translational and biomarker activities. Dr. Candia received his B.A. in Biology and Chemistry from Bucknell University and a Ph.D. in Cell Biology from Vanderbilt University School of Medicine.

Stephen F. Carroll, Ph.D. 

Dr. Carroll joined us in 2015 and is our Distinguished Research Fellow in Preclinical Sciences. Previously, Dr. Carroll spent 17 years in various scientific and leadership positions at Xoma, a biotechnology company, including Vice President of Preclinical Research and Scientific and Product Development.  Dr. Carroll received a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Microbiology from the University of California, Los Angeles. He also completed a post doctorate in Microbiology at the University of California, Los Angeles, and he was an Assistant Professor in the Department of Microbiology and Molecular Genetics at Harvard Medical School.

Lisa L. Decker, Ph.D.

Dr. Decker has served as our Chief Business Officer since March 2021. Prior to joining us, Dr. Decker served as Chief Business Officer of Atreca, a biopharmaceutical company, from June 2019 until March 2021. Dr. Decker also previously served in various roles at Nektar Therapeutics, a development stage biopharmaceutical company, from August 2008 to June 2019, including as Vice President of Business Development from August 2017 until June 2019, Executive Director, Business Development from August 2012 until August 2017, Executive Director, Business Strategy and Operations from January 2010 until July 2012, and Senior Director, Alliance Management from August 2008 until December 2009. Prior to this, Dr. Decker served in a number of roles at the Office of Technology Management at the University of Massachusetts Medical School from 2000 until 2008. Dr. Decker holds a Ph.D. in Immunology from Tufts University School of Medicine and conducted her postdoctoral training at Harvard Medical School.

Elizabeth (Betsy) Haanes, Ph.D., J.D.

Dr. Haanes joined us in 2019 and serves as our Senior Vice President of Intellectual Property. Her legal career spans 24 years as a patent agent/attorney building patent portfolios for small to midsize biotechnology companies, representing and advising clients in myriad aspects of IP law, including freedom to operate, licensing, IP diligence on M&A, partnering deals, and financings, and non-district court-related patent challenges including interferences, inter-partes reexaminations, and inter-partes reviews. Dr. Haanes also has extensive technology experience in infectious diseases (vaccines and therapeutics), oncology, neurology, autoimmunity, and inflammation and platform experience in vaccines, recombinant antibodies, non-antibody protein therapeutics, and nucleic acid-based therapeutics. Prior to joining IGM, Dr. Haanes served biotechnology clients in private practice as a Partner at FisherBroyles, LLP and at Thompson Coburn, LLP, and as a Director at Sterne, Kessler, Goldstein & Fox, PLLC. Dr. Haanes received a B.S. in Biology at the University of Michigan, a Ph.D. in Microbiology at the University of Minnesota and a J.D. at the University of Colorado. Dr. Haanes is admitted to practice in the District of Columbia and in patent cases before the United States Patent and Trademark Office. Dr. Haanes is also a Registered In-House Counsel in California.

TS Harigopal

Mr. Harigopal joined us in 2021 and serves as our Senior Vice President of Group Operations overseeing the Information Technology, Facilities and Procurement functions. Mr. Harigopal has over 25 years of experience in the life sciences industry. Prior to joining us, Mr. Harigopal was Director of Information Technology at Cytokinetics, a public, clinical-stage biotechnology company. Prior to Cytokinetics, he held IT roles in various capacities in Pharmacyclics (acquired by Abbvie) and Johnson & Johnson. Mr. Harigopal received his BA in Finance and Information Technology from the University of Bombay, and an MBA with specialization in Finance and Global Supply Chain from the California State University, East Bay.

Mary Beth Harler, M.D.

Dr. Harler has served as President, IGM Autoimmunity and Inflammation since 2021. Prior to joining IGM she was Senior Vice President, Head of Immunology and Fibrosis Development at Bristol Myers Squibb, where she oversaw late-stage development of assets for the potential treatment of psoriasis, inflammatory bowel disease (IBD) and nonalcoholic steatohepatitis (NASH), among others. Dr. Harler also oversaw approved medicines within the immunology and fibrosis  portfolios, such as Orencia and Zeposia. In her more than 10 years at Bristol Myers Squibb she also served as Head of Innovative Medicines Development and Head of Innovative Clinical Development in the cardiovascular, fibrosis, immunoscience and genetically-defined diseases group. Prior to joining Bristol Myers Squibb, Dr. Harler worked in both medical affairs and clinical research at Wyeth Pharmaceuticals (now part of Pfizer). Dr. Harler received a B.S. from Wheeling University in West Virginia and an M.D. from Marshall University. She completed training as a general surgeon at Brown University’s Rhode Island Hospital, where she was also a research fellow with a focus on the role of immune cells in wound healing.

Marvin S. Peterson, Ph.D.

Dr. Peterson joined us in 2017 and serves as our Executive Vice President of Process Sciences and Manufacturing. Dr. Peterson also served as Senior Director, Manufacturing at MabVax Therapeutics, a biotechnology company, from 2015 to 2017 and as Senior Director, Upstream Process Development and Manufacturing at Ambrx, a biotechnology company, from 2014 to 2015. Dr. Peterson has also served in manufacturing, scientific and leadership positions at Bristol-Myers Squibb, Eli Lilly, Celgene and Shire. Dr. Peterson received a B.S. in Chemical Engineering from the University of Colorado, Boulder and a Ph.D. in Chemical Engineering from Purdue University. He also completed a post doctorate at the University of Minnesota, BioProcess Technology Institute.